Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OReO: olaparib rechallenge maintenance in recurrent platinum-sensitive epithelial ovarian cancer after prior PARP inhibitor
MOH_2017-11-02_000739Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing olaparib with placebo (2 arms). Planned start Aug 2017; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2017-11-02_000739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-02_000739.